BioSpace News Archive

Drug Development

Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting

Two of the five fatalities were found to be unrelated to MacroGenics’ investigational antibody-drug conjugate vobra duo, while the other three are still under investigation.

May 10, 2024
·
2 min read
·
Tristan Manalac
Business

Bluebird Boasts Nearly 140% Revenue Jump, Still Misses Target

With 15 patients started across its three gene therapies, bluebird bio claims a 138% year-over-year revenue growth and aims to initiate up to around 100 new patients in the current year.

May 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise

While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how far we are from widespread use.

May 10, 2024
·
4 min read
·
Greg Slabodkin
Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine

Sanofi will hand Novavax $500 million upfront for its COVID-19 vaccine, which it will co-commercialize and develop into a combination flu-COVID vaccine.

May 10, 2024
·
1 min read
·
Kate Goodwin
Business

Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS Therapy

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy frexalimab, which is currently in Phase III trials for multiple sclerosis.

May 10, 2024
·
2 min read
·
Tristan Manalac
Policy

Verona Secures Up To $650M in Funding as it Gears Up for Potential COPD Approval and Launch

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree Capital Management and OMERS Life Sciences.

May 10, 2024
·
2 min read
·
Tristan Manalac
ASGCT24: Translational Research Powering Potentially Transformative Therapies

Friday’s agenda highlighted some of the pivotal translational studies, as well as the researchers who are making breakthroughs in genetic therapies.

May 10, 2024
·
2 min read
·
Greg Slabodkin
Drug Development

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US.

May 10, 2024
·
7 min read
Business

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

May 10, 2024
·
6 min read
Pharm Country

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc. announced longer-term data updates from its lentiviral vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy.

May 10, 2024
·
16 min read